Skip to main content
大禹生物 logo

大禹生物 — Investor Relations & Filings

Ticker · 920970 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 384 across all filing types
Latest filing 2022-05-30 Share Issue/Capital Cha…
Country CN China
Listing Beijing Stock Exchange 920970

About 大禹生物

http://www.sxdysw.cn/

Shanxi Dayu Biological Assistance Co., Ltd. specializes in the research, development, and production of advanced animal nutrition and health solutions. The company focuses on the manufacturing of feed additives, micro-ecological preparations, and biological feed products. Its core portfolio includes probiotics, enzyme preparations, and functional premixes designed to enhance livestock immunity, improve feed conversion rates, and promote sustainable farming practices. By leveraging biotechnology, the firm provides integrated solutions for the aquaculture and animal husbandry sectors, emphasizing scientific innovation and product quality to support the modernization of the agricultural supply chain.

Recent filings

Filing Released Lang Actions
关于拟变更公司注册资本、类型及修订公司章程公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the proposed changes to the company's registered capital, company type, and amendments to the Articles of Association. It references regulatory compliance with company law and securities regulations, and it mentions that the changes are subject to shareholder approval. The document does not contain financial statements or detailed financial data but is a formal announcement of corporate governance changes related to capital and company structure. It is not a full annual or interim report, nor an earnings release or audit report. It is not a report publication announcement since it contains substantive content about the changes. The document fits best under Share Issue/Capital Change (SHA) as it concerns changes in registered capital and company type due to a public stock issuance and listing.
2022-05-30 Chinese
第三届监事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the third Supervisory Board of Shanxi Dayu Biological Engineering Co., Ltd. It details meeting attendance, agenda items, voting results, and references to related announcements on the Beijing Stock Exchange website. The content focuses on internal governance decisions regarding the use of raised funds and related approvals. It does not contain financial statements, audit opinions, or detailed financial data. It is not a full annual or interim report, nor is it a call transcript or earnings release. The document is a formal disclosure of board-level decisions and meeting resolutions, which fits the category of Board/Management Information (MANG). The document length is short (1731 characters), and it is not merely announcing the publication of a report but is itself the meeting resolution announcement. Therefore, the appropriate classification is MANG with high confidence.
2022-05-30 Chinese
第三届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the third board of directors of Shanxi Dayu Biological Engineering Co., Ltd. It details the meeting's attendance, the agenda items discussed, voting results, and references to related announcements on the Beijing Stock Exchange website. The content focuses on board decisions regarding changes in registered capital, use of raised funds, and scheduling of a shareholders' meeting. There are no financial statements or detailed financial data presented, nor is this a transcript or presentation. The document is a formal board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 2693 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report.
2022-05-30 Chinese
安信证券股份有限公司关于山西大禹生物工程股份有限公司使用闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from a sponsoring securities firm (安信证券股份有限公司) regarding the use of idle raised funds by 山西大禹生物工程股份有限公司 to temporarily supplement working capital. It references regulatory frameworks related to securities issuance and listing on the Beijing Stock Exchange, details about the fundraising amount, and the company's board and supervisory approvals. The document is a verification or audit opinion on the use of funds rather than a full financial report or earnings release. It does not contain financial statements or detailed financial performance data but rather a compliance and procedural check. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and verification opinions related to regulatory compliance and fund usage, excluding full annual or interim reports. Q2 2022
2022-05-30 Chinese
关于使用募集资金置换预先已投入募投项目及已支付发行费用的自筹资金公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanxi Dayu Bioengineering Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in projects and paid issuance expenses. It details the approval by the board and supervisory committee, references regulatory approvals from the Beijing Stock Exchange and China Securities Regulatory Commission, and includes financial figures related to the fundraising and fund usage. The document is relatively short (3750 characters) and primarily serves as a formal disclosure of a financing update related to the company's capital structure and use of proceeds. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It also does not fit categories like Board/Management changes, Earnings Release, or Legal Proceedings. The content aligns best with a Capital/Financing Update (CAP) as it discusses fundraising, use of proceeds, and related approvals.
2022-05-30 Chinese
独立董事关于第三届董事会第三次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on specific proposals related to the use of raised funds by the company. It discusses the legality and appropriateness of using raised funds for certain purposes, such as replacing self-raised funds, supplementing working capital, and purchasing financial products. The document is a formal announcement of the independent directors' opinions rather than a full financial report or audit. It does not contain financial statements or detailed financial data. It is also not a report publication announcement or a certification letter. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement related to corporate governance and compliance with fundraising regulations.
2022-05-30 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.